RecruitingNot ApplicableNCT06026189
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Sponsor
Erasmus Medical Center
Enrollment
1,100 participants
Start Date
May 31, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.
Eligibility
Inclusion Criteria3
- Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
- Male patients ≥40 years
- Female patients ≥50 years
Exclusion Criteria3
- History of urothelial bladder- or urinary tract cancer
- Presence of macroscopic (visible) hematuria
- Woman who is or may be pregnant
Interventions
DIAGNOSTIC_TESTurine-first strategy
Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06026189
Related Trials
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT000268841 location
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT0712999379 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT074754031 location
Bio Clinical Collection of Urothelial Carcinoma
NCT049704721 location